Steroid Dosage and Tapering in Pure Neuritic Leprosy
For pure neuritic leprosy, initiate prednisolone at 40 mg daily (or 1 mg/kg/day) alongside multidrug therapy, maintain this dose for 12 weeks, then taper by 5 mg every 2 weeks over the subsequent 8 weeks, completing treatment by 20 weeks. 1
Initial Dosing Strategy
Start prednisolone at 40 mg daily (approximately 1 mg/kg/day) at the time of diagnosis, given concurrently with standard multibacillary multidrug therapy (MB-MDT). 2, 1 This dosing applies whether the patient presents with acute neuritis, type 1 or type 2 reactions, or silent neuropathy. 2
- Higher initial doses (2 mg/kg/day) show better results only in the first month, but early treatment with 1 mg/kg/day proves equally effective by 6 months. 1
- The 40 mg daily dose represents the standard therapeutic approach for leprosy neuropathy with established nerve function impairment. 2
Maintenance Phase
Continue the full 40 mg daily dose for 12 weeks (3 months) without reduction. 2, 3 This duration is critical for adequate disease control before initiating any taper.
- Prophylactic prednisolone at 20 mg daily for 3 months shows significant benefit in preventing nerve function impairment at 4 months, though this effect diminishes by 12 months. 3
- For established neuritic leprosy (not prophylaxis), the higher 40 mg dose for the full 12 weeks is necessary given that nerve damage is already present. 2
Tapering Schedule
After 12 weeks at 40 mg daily, begin tapering by 5 mg every 2 weeks:
- Week 12-14: 35 mg daily
- Week 14-16: 30 mg daily
- Week 16-18: 25 mg daily
- Week 18-20: 20 mg daily
- Complete taper by week 20 (5 months total duration) 4
This structured taper prevents disease rebound while minimizing long-term steroid exposure. 4
Duration Considerations
Total treatment duration should be at least 5 months (20 weeks), with some evidence supporting extension to 8 months in multibacillary cases. 4
- A study using prophylactic prednisolone 20 mg daily for 6 months followed by tapering over months 7-8 showed significantly better prevention of nerve function deterioration compared to MDT alone. 4
- For pure neuritic leprosy with established impairment, the 5-month regimen (12 weeks full dose + 8 weeks taper) represents the minimum effective duration. 2, 1
Type 2 Reactions
In type 2 reactions (erythema nodosum leprosum), shorter steroid courses are effective: Start at 1 mg/kg/day and taper to 0.5 mg/kg/day or less within one month. 1 This differs from the longer course needed for type 1 reactions and pure neuritic presentations.
Critical Monitoring Points
Assess nerve function at baseline, 8 weeks, 12 weeks (before taper), and at completion of therapy using:
- Monofilament testing for sensory function
- Voluntary muscle testing for motor function
- Nerve palpation for tenderness
- Nerve conduction studies when available (most sensitive for detecting subclinical involvement) 2
Nearly all multibacillary patients show peripheral nerve abnormalities on nerve conduction studies regardless of clinical presentation, emphasizing the importance of early aggressive treatment. 2
Common Pitfalls
- Avoid premature tapering: Beginning taper before 12 weeks risks inadequate disease control and rebound nerve damage. 2, 1
- Don't use prophylactic doses for established disease: The 20 mg prophylactic dose is insufficient for patients presenting with nerve function impairment; use 40 mg instead. 2, 3
- Recognize that lower doses work if started early: If treatment begins immediately at diagnosis, 1 mg/kg/day is as effective as 2 mg/kg/day by 6 months, but delays necessitate higher doses. 1
- Monitor for steroid-related complications: Given the 5-8 month duration, assess for hyperglycemia, hypertension, weight gain, and bone density loss throughout treatment. 5
Adjunctive Measures
Combine corticosteroids with:
- Standard MB-MDT for 12 months minimum 4, 6
- Pain management strategies 6
- Physiotherapy to prevent contractures 6
- Self-care education for insensate limbs 6
High-resolution ultrasonography can objectively document nerve thickening and monitor treatment response, though clinical assessment remains the primary guide. 6